Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...

A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in ...

Vimentin is a type III intermediate filament (IF) protein normally expressed in cells that develop into connective tissue, ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Six new drugs, including a treatment for patients with advanced breast cancer, have been approved for use by the NHS in ...

Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner.

New research has found that changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth.

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Vimentin is a type III intermediate filament (IF) protein normally expressed in cells that develop into connective tissue, blood vessels, and ...

Vimentin is a type III intermediate filament (IF) protein typically expressed in cells that differentiate into connective ...